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Abstract
Skeletal muscle represents between 30 and 38% of the human body mass. Both 
the maintenance and repair of adult muscle tissue are directed by satellite cells 
(SCs). SCs are located beneath the basal lamina of the skeletal muscle myofiber. 
They are quiescent for most of their life but, in response to physiological stimuli or 
muscle trauma, they activate, proliferate, and enter the myogenic program via gen-
erating myogenic progenitors (myoblasts) that fuse to existing myofibers or de novo 
myofibers. MicroRNAs (miRNAs or miRs) play a critical role in regulating muscle 
regeneration and stem cell behavior. In this chapter, we review the pivotal role in 
the regulation of SC quiescence, activation, and differentiation in the context of 
muscular dystrophies.
Keywords: microRNA, satellite cell, quiescence, myogenesis, muscle regeneration, 
muscular dystrophies
1. Introduction
With more than 600 individual muscles in humans, skeletal muscle tissue 
represents between 30 and 38% of the human body mass [1]. This tissue is essential 
not only to provide ambulatory capacity to our organism but also to control such 
important functions as breathing and thermogenesis. Although its composition is 
heterogenous, each single skeletal muscle is mainly composed by individual muscle 
fibers consisting of elongated multinucleated syncytia. These myofibers are diversi-
fied in size, shape, and contractile protein content to fulfill the different functional 
needs of our body. This tissue retains a highly adaptive and robust capacity to regen-
erate throughout most of life, thanks to the presence of a stem cell-like population 
termed as satellite cells (SCs) [2].
miRNAs have emerged as critical regulators of numerous biological processes 
by modulating gene expression at the posttranscriptional level. The discovery of 
miRNAs as new and important regulators of gene expression is expected to broaden 
our biological understanding of the regulatory mechanism in muscle by adding 
another dimension of regulation to the diversity and complexity of gene regula-
tory networks. In that context, the role of miRNAs in SC biology is beginning to be 
explored. In this chapter, we will focus in our understanding of how miRNAs act in 
controlling the ability of SCs to appropriately balance SC function during muscle 
regeneration as well as in the context of neuromuscular diseases.
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2. Basic biology of SCs
SCs, originally identified via electron microscopy in 1961 by Alexander Mauro, 
are located underneath the basal lamina and adjacent to the plasma membrane of 
the skeletal muscle myofiber [3]. It has been established that SCs in adult muscle 
represent a lineage continuum of embryonic myogenic progenitor cells. SCs of 
the body and limbs arise from somites, in common with the muscle that they are 
associated with [4–6], while SCs located in head muscles also originate from the 
cranial mesoderm [7]. In undamaged muscle, the majority of satellite cells are 
quiescent, characterized by the expression of the transcription factor PAX7 [8]. 
Within a context of physiological stimuli (physical exercise or pathological condi-
tions), SCs become activated and enter into the cell cycle to expand their progeny 
and form myogenic precursor cells or myoblasts [8]. SCs’ activation is mediated by 
the induced expression of myogenic factor 5 (MYF5) and myogenic determination 
protein (MYOD) [2]. The differentiation of myogenic committed cells involves 
downregulation of PAX7 and de novo expression of myogenin (MYOG), which is 
followed by fusion of the newly formed differentiated myoblasts among them and 
with the remaining myofibers to repair damaged muscle [2]. In addition to provid-
ing myogenic precursors, activated SCs also undergo self-renewing proliferation 
that replenishes the pool of muscle SCs, thereby ensuring that the capacity to 
respond to future injuries is maintained in the muscle [2].
3. Biogenesis of miRNAs
Canonical miRNAs are transcribed by RNA polymerase II into primary tran-
scripts called pri-miRNA, bearing 5′m7G cap and 3′ poly(A) tail structures [9]. 
Sometimes, miRNA loci can comprise no single but multiple and overlapping 
miRNA genes, called clusters, which are processed from the same polycistronic 
primary transcript [10]. Once transcribed, the pri-miRNA forms a stem-loop 
structure. Then, the RNA-binding protein Di George syndrome critical region gene 
8 (DGCR8) recognizes it and directs the nuclear RNase III enzyme endonuclease, 
DROSHA, toward the pri-miRNA. DROSHA cleaves at the base of the hairpin 
embedded within the pri-miRNA [11], yielding a ∼70-nt hairpin molecule termed 
precursor miRNA or pre-miRNA. Soon after, the pre-miRNA is transported from 
the nucleus by exportin 5 to the cytoplasm via a Ran-GTP-dependent mechanism 
[12]. Once in the cytoplasm, a second RNase III endonuclease, DICER, cleaves the 
pre-miRNA, thus removing the terminal loop of the pre-miRNA and releasing a 
mature double-stranded ∼22-nt miRNA molecule [13]. One strand of this duplex 
RNA molecule (the guide strand) is transferred to the RNA-induced silencing com-
plex (RISC) containing argonaute 2 (AGO2) and the RNA-binding protein TARBP2 
[TAR (HIV) RNA-binding protein 2], while the other is degraded [14]. The miRNA’s 
function at this time is to guide the silencing complex to the target mRNA through 
complementary binding of the miRNA seed sequence, which results in inhibition of 
translation and/or degradation of the target transcript [15] (Figure 1).
Approximately, half of vertebrate miRNAs are processed from introns of 
protein-coding genes or genes encoding for other ncRNA classes, for instance, 
small nucleolar RNA (snoRNAs) or long intervening noncoding RNAs (lincRNAs) 
[10]. The biosynthesis of these miRNAs bypass one or more steps in the canonical 
biogenesis pathway, being therefore termed noncanonical miRNAs. In this sense, it 
is important to stress that while DROSHA and DGCR8 are only needed to process 
canonical miRNAs, DICER is almost always indispensable in the production of both 
canonical and noncanonical miRNAs [16]. Among noncanonical miRNAs, the most 
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studied have been those so-called miRtrons, located within intron sequences. The 
expression profiles of these miRNAs coincide with the transcription of their host 
genes [10], being released from the excised host introns by the spliceosome [17, 18] 
in a typical mirtron-maturing fashion (Figure 1).
4. miRNAs and SC function
Deep sequencing analyses have shown that many miRs are expressed in muscle 
tissue [19–21]. Among these miRs, there is a group, so-called myomiRs, whose 
expression is restricted to muscle tissue. This family is composed by miR-1, miR-
133a, and miR-206, miR208a, miR-208b, miR-486, and miR-499 [22–28]. While 
Figure 1. 
Schematic representation of biogenesis of miRNAs.
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most myomiR family members are expressed in both the heart and skeletal muscle, 
miR-208a is cardiac-specific and miR-206 is skeletal muscle-specific. A deeper 
analysis of these family members is well reviewed in [29]. Nevertheless, not only 
myomiRs but also other miRs with a more ubiquitous expression play important 
roles in the muscle. It has also been shown that miRNAs are essential for muscle 
homeostasis and regeneration upon injury, since either systemic or conditional 
deletion of DICER in muscle PAX7+ population results in a depletion of SCs and 
a quasi-absence of repair upon injury cell [30]. In addition, to date, in vitro and 
in vivo experiments have shown that many miRs expressed in the skeletal muscle 
rule quiescence, activation, proliferation, fate specification, and differentiation of 
muscle progenitor cells by regulating the expression of myogenic differentiation 
regulators, transcription factors, structural proteins, and cytoskeletal components 
that are required to give rise to the differentiated muscle phenotype. In this section, 
we will review some of them, analyzing their roles in quiescence, activation-prolif-
eration, and differentiation estates.
4.1 Control of the quiescence state
In vivo, SCs are normally in a quiescent state after the postnatal development. 
Cheung et al. showed that the quiescent state is strongly controlled by miRs, since 
SCs lacking a functional Dicer gene, spontaneously exit from the quiescent state 
[30]. In this work, the authors demonstrate that miR-489 regulates SCs quiescence 
in a cell-autonomous manner through the control of the oncogene Dek (DEK proto-
oncogene), whose protein is not expressed in quiescent SCs (QSCs) but is strongly 
upregulated after SC activation. Soon after, Crist et al. showed that miR-31 targets 
Myf5 mRNA in QSCs, thus preventing MYF5 protein accumulation and premature 
activation of these muscle stem cells [31]. miR-31 is sequestered with Myf5 transcripts 
in cytoplasmic mRNP granules in QSCs and, upon SCs’ activation, these mRNPs rap-
idly dissociate and relieve the spatial constraint on miR-31 and Myf5 mRNA, allowing 
the rapid translation of the MYF5 protein. Recently, Baghdadi et al. have added a new 
miR to the list of miRs that control the quiescent state of SCs [32]. In this work, the 
authors shown that miR-708 regulates quiescence and self-renewal by active repres-
sion of SC migration. Notch signaling is directly implicated in this control by induc-
ing transcription of miR-708 that represses Tensin3 (Tns3), a component of the focal 
adhesion complex. This repression inhibits focal adhesion kinase (FAK) activation, 
which in turn stabilizes SCs within their niche (Table 1 and Figure 2).
4.2 Activated proliferative state
Early evidences of miRs controlling proliferation in myoblast were reported by 
Chen et al. in 2006 [33]. In this work, the authors showed that miR-133 enhances 
myoblast proliferation by repressing the serum response factor (Srf) in vitro and in 
vivo in Xenopus laevis embryos. Similarly, Cai et al. have recently shown that miR-
664 also promotes myoblast proliferation by targeting Srf mRNA [34]. Other miR 
that proposed to promote myoblast proliferation is miR-27. Huang et al. showed that 
miR-27, for this purpose, targets myostatin (Mstn), a well-known negative regulator 
of myogenesis [35]. Sometimes, miR members of a same cluster can work together 
in order to achieve the same biological effect. In this sense, Qiu et al. have shown 
that miR-17, miR-20a, and miR-92a, three members of the miR-17-92 cluster, 
repress PDZ and LIM domain 5 (Pdlim5), also known as Enh1 expression at heart 
and skeletal muscle. This protein exerts antiproliferative effects in myoblast. Thus, 
its inhibition contributes to promote myoblast proliferation and prevents differen-
tiation [36] (Table 1 and Figure 2).
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microRNAs Targets Function References
miR-489 Dek Regulates SCs’ quiescence [30]
miR-31 Myf5 Prevents MYF5 protein accumulation 
and premature activation of SCs
[31]
miR-708 Tns3 Regulates quiescence and self-renewal by 
active repression of SCs’ migration
[32]
miR-133 Srf Enhances and/or promotes myoblast 
proliferation
[33]
miR-664 Srf Enhances and/or promotes myoblast 
proliferation
[34]
miR-27 Mstn Enhances and/or promotes myoblast 
proliferation
[35]
miR-17, miR-20a, and 
miR-92a
Pdlim5 Enhance and/or promotes myoblast 
proliferation
[36]
miR-195 and miR-497 Igf1r, Insr, Ccne1, 
and Ccnd2
Inhibit myoblast proliferation [37]
miR-487b Irs1 Inhibits myoblast proliferation [38]
miR-16 Foxo1 Suppresses myogenesis [39]
miR-1 and miR-133 Ccnd1 and Sp1 Inhibit myoblast proliferation [40]
miR-15b, miR-23b, 
miR-106b, and 
miR-503
Ccnd1 and Ccnd2 Keep SCs in a quiescent state [41]
miR-106b Myf5 Keeps SCs in a quiescent state [41]
miR-1 Hdac4 Promotes myoblast differentiation [33]
miR-1 and miR-206 Pax7 Restrict myogenic progenitor cell 
proliferation and promote differentiation
[42]
miR-206 Pax7 Activates myoblast differentiation [43]
miR-206 Pax7, Notch3, and 
Igfbp5
Stimulates SC differentiation and 
skeletal muscle regeneration
[44]
miR-206 Hdac4 and Pola1 Promotes myoblast differentiation and 
induces a cell cycle arrest
[45]
miR-1 and miR-206 Gja1 Promote myoblast fusion [46]
miR-206 and miR-486 Pax7 Promote initial muscle differentiation [47]
miR-486 Pten, Pdgfrβ, 
Foxo1, Sfrs1, and 
Sfrs3
Promotes myoblast differentiation [48–50]
miR-133 Fgfr1 and Pp2ac Promotes muscle precursor cells 
differentiation
[51]
miR-29 Rybp and Yy1 Ensures proper myoblast differentiation 
into myotubes
[52]
miR-29 Hdac4 Promotes myoblast differentiation [53]
miR-29 Akt3 Reduces proliferation and facilitates 
differentiation of precursor muscle cells
[54]
miR-26a Ezh2 Induces muscle cell differentiation [55]
miR-26a Smad1 and Smad4 Promotes myoblast differentiation [56]
miR-214 Ezh2 Promotes myoblast differentiation [57]
miR-214 N-ras Promotes myogenic differentiation by 
facilitating exit from mitosis
[58]
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miRNAs can modulate negative proliferation in myoblast as well. In this sense, 
Wei et al. showed that the protein complex NF-κB can induce miR-195 and miR-497 
expression, thus inhibiting myoblast proliferation by targeting insulin-like growth 
factor I receptor (Igf1r), insulin receptor (Insr), cyclin E1 (Ccne1), and cyclin D2 
(Ccnd2) mRNAs [37]. Thus, NF-κB inhibition must be accomplished to induce 
proliferation in these cells. Another miR that targets insulin signaling proteins is 
miR-487b. This miR represses insulin receptor substrate 1 (Irs1) mRNA, thus exert-
ing a negative control of myoblast proliferation [38]. Similarly, it has been reported 
that miR-16 acts as a coordinated mediator that can suppress myogenesis in avian 
hypertrophic skeletal muscles through the control of myoblast proliferation by 
targeting forkhead box O1 (Foxo1) mRNA [39], a transcription factor that governs 
muscle growth, metabolism, and cell differentiation [69]. Growth factors such as 
fibroblast growth factors (FGFs) regulate cell proliferation and differentiation in 
numerous tissues, including skeletal muscle [70]. In this sense, Zhang et al. [40] 
have shown that FGF2 released from the myotrauma represses p38 signaling and 
expression of miR-1 and miR-133. Thus, the repressed p38 signaling and subse-
quent downregulation of miR-1 and 133 induce an upregulation of their respective 
targets, cyclin D1 (Ccnd1) and Sp1 transcription factor (Sp1), that jointly facilitate 
the SC proliferation at the early stages of muscle regeneration. Nevertheless, this 
work contradicts the pro-proliferating role for miR-133 proposed by Chen et al. in 
2006 [33]. Our group has also shed light over this issue. Thus, Lozano-Velasco et al. 
unravel the existence of a Pitx2-miRNA pathway that modulates cell proliferation 
in myoblasts and skeletal muscle SCs [41]. In this work, we demonstrated that 
miR-15b, miR-23b, miR-106b, and miR-503 keep SCs in a quiescent state by target-
ing Ccnd1 and Ccnd2. Once QSCs are activated, Pitx2c is upregulated and exerts a 
microRNAs Targets Function References
miR-181 HoxA11 Promotes myogenic differentiation [59]
miR-378 MyoR Promotes myogenic differentiation [60]
miR-205a Cdh11 Inhibits myoblast proliferation and 
promotes myoblast differentiation
[61]
MiR-675-3p Smad1 and Smad5 Promotes myogenic differentiation by 
repression of BMP pathway
[62]
miR-675-5p Cdc6 Promotes myogenic differentiation by 
repression of DNA replication
[62]
miR-17 Ccnd2, Jak1, and 
Rhoc
Promotes differentiation of precursor 
muscle cells
[63]
miR-34b Igfbp2 Represses proliferation and promotes 
differentiation of myoblasts
[64]
miR-664 Wnt1 Downregulates WNT signaling to allow 
for normal myogenic differentiation to 
occur
[34]
miR-199a Wnt2, Fzd4, and 
Jag1
Downregulates WNT signaling to allow 
for normal myogenic differentiation to 
occur
[65]
miR-155 Mef2a Represses myoblast differentiation [66]
miR-351 Lactb Represses myoblast differentiation [67]
miR-23a Myh1, Myh2, and 
Myh4
Prevents myogenic differentiation [68]
Table 1. 
General overview of miRNAs involved in adult myogenesis.
7miRNAs and Muscle Stem Cells
DOI: http://dx.doi.org/10.5772/intechopen.92851
Figure 2. 
miR controlling differentiation of muscular precursor cells. Green and red labels correspond with the induced 
or repressed molecules on each state, respectively (quiescent state, activated proliferative state, or myogenic 
differentiation).
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repressive effect over miR-15b, miR-23b, miR-106b, and miR-503 promoters, thus 
allowing Ccnd1 and Ccnd2 mRNA to be translated. On the other hand, this Pitx2 
upregulation also avoids the repressive effect of miR106b over Myf5 mRNA, thus 
promoting myoblast commitment to a myogenic cell fate (Table 1 and Figure 2).
4.3 Myogenic differentiation
SC differentiation is a complex process. In this stage, the cells need to switch 
off proliferative signals and upregulate structural genes turning simple individual 
cells into a complex syncytium with the ability to coordinately contracts. In this 
scenario, miRs have also been described as essential molecules. Focusing on myo-
miRs, Chen et al. showed that miR-1 promotes myoblast differentiation by targeting 
histone deacetylase 4 (Hdac4) mRNA, a transcriptional repressor of muscle gene 
expression [33]. HDAC4 has been shown to inhibit muscle differentiation and 
skeletal muscle gene expression, mainly by repressing myocyte enhancer factor 
2C (MEF2C), an essential muscle-related transcription [71]. The same group also 
showed that miR-1 and miR-206 restrict myogenic progenitor cell proliferation and 
promote differentiation by directly downregulating Pax7 expression [42]. At the 
same time, Cacchiarelli et al. also showed that miR-206 activates myoblast differen-
tiation through Pax7 repression at early stages of differentiation [43]. These authors 
have shown that, in SCs, miR-206 is specifically repressed by histone deacetylase 1 
(HDAC1), but under differentiation conditions, repressive effect over miR-206 pro-
moter mediated by HDAC1 disappear thus allowing Pax7 repression and promoting 
myoblast differentiation [43]. Soon after, Liu et al. showed that loss of miR-206 
results in upregulation of Pax7, notch receptor 3 (Notch3), and insulin-like growth 
factor-binding protein 5 (Igfbp5) in differentiating miR-206 KO SCs compared 
with WT cells, implying that repression of these inhibitors of myogenesis accounts, 
at least in part, for the stimulatory influence of miR-206 on SC differentiation and 
skeletal muscle regeneration [44]. As miR-1, miR-206 also promotes myoblast 
differentiation by targeting Hdac4 [53] and induces a cell cycle arrest through the 
repression of DNA polymerase alpha 1 (Pola1, catalytic subunit), a specific subunit 
of DNA polymerase α [45]. miR-1 and miR-206 also work coordinately, downregu-
lating gap junction protein (Gja1, alpha also known as Connexin 43) expression 
during myoblast fusion as Anderson et al. had shown previously [46]. Dey et al. also 
corroborated that miR-206 targets Pax7 mRNA [47] and, in the same work, they 
also demonstrated that miR-486 exerts the same effect in order to promote initial 
muscle differentiation. Regarding this miR, Alexander et al. showed that miR-486 
targets phosphatase and tensin homolog (Pten), platelet-derived growth factor 
receptor beta (Pdgfrβ), Foxo1, serine and arginine-rich splicing factor 1 (Sfrs1), 
and serine and arginine-rich splicing factor 3 (Sfrs3) mRNAs. Proteins derived 
from these mRNAs comprise the PTEN/AKT pathway, which is essential for normal 
cellular proliferation [48–50]. Thus, miR-486 overexpression and consequent 
PTEN/AKT pathway inhibition are required for proper myoblast differentiation as 
well. A role for miR-133 in myogenic differentiation has also been proposed. Thus, 
Feng et al. showed that miR-133 promotes muscle precursor cells differentiation by 
downregulating two members of the pro-proliferation ERK1/2 signaling pathway, 
fibroblast growth factor receptor 1 (Fgfr1), and protein phosphatase 2 (Pp2ac, cata-
lytic subunit, alpha isozyme) [51]. All together, these data bring out the important 
role carried out by myomiRs during early steps of muscle differentiation (Table 1 
and Figure 2).
Focusing on non-muscle-specific miRs involved in myogenic differentiation, 
another miR with a relevant importance during muscle differentiation is miR-29. 
miR-29 seems to promote myogenesis by downregulating multiple targets related 
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to the NF-kB signaling pathway. In this sense, Wang et al. unraveled a myogenic 
circuit that involves constitutive activity of NF-kB in myoblasts regulating the YY1 
transcription factor, which subsequently suppresses the miR-29 promoter activity 
by recruiting the enhancer of zeste homolog 2 (histone methyltransferase, EZH2) 
as well as the histone deacetylase protein HDAC1, thus maintaining cells in an 
undifferentiated state [72]. In this regard, Zhou et al. later showed that miR-29 is 
able to directly target the RING1- and YY1-binding protein (Rybp) [52]. RYBP is a 
negative regulator of skeletal myogenesis, which, together with EZH2 and HDAC1, 
functions as a corepressor of YY1 to silence miR-29 promoter [52]. Thus, as dif-
ferentiation ensues, downregulation of the NF-kB-YY1 pathway, RYBP, and EZH2 
lead to upregulation of miR-29 that in turns further decreases YY1 and Rybp levels 
to ensure proper differentiation into myotubes. As miR-1 and miR-206, miR-29 also 
promotes myoblast differentiation by targeting Hdac4 [53]. In addition, miR-29 
targets AKT serine/threonine kinase 3 (Akt3), a member of the serine/threonine 
protein kinase family responsive to growth factor cell signaling, to reduce prolif-
eration and facilitate differentiation of precursor muscle cells in skeletal muscle 
development [54] (Table 1 and Figure 2).
Another non-muscle-specific miR whose expression is upregulated during myo-
genic differentiation is miR-26a. The important role of miR-26 in inducing muscle cell 
differentiation had also been previously demonstrated by Wong et al., who showed 
that miR-26 acts to posttranscriptionally repress Ezh2, a known suppressor of skeletal 
muscle cell differentiation that belongs to the polycomb group (PcG) of proteins that 
suppress gene transcription through histone methylation, thus promoting miR-29 
promoter activity as we have previously indicated [55]. In addition, Dey et al. showed 
that miR-26a directly targets SMAD family member 1 (Smad1) and SMAD family 
member 4 (Smad4), two critical transcription factors that belong to TGF-β/BMP 
pathway, whose activity inhibits myogenesis [56] (Table 1 and Figure 2).
miR-214 upregulation is also required for myogenesis. During SCs’ activation 
and proliferation, EZH2 is highly expressed in the generated myoblasts, thus allow-
ing PcG proteins to repress transcription from the intronic region containing miR-
214 [57]. The initial phase of cell differentiation is characterized by reduced Ezh2 
expression and consequent derepression of the miR-214 locus. Then, in a negative 
feedback, miR-214 targets Ezh2 mRNA, thus reducing its translation [57]. At this 
point, the continuous PcG disengagement leads to recruit MyoD/MyoG to the 
miR-214 promoter, thus enhancing its transcription [57]. This negative feedback, 
together with miR-26a via Ezh2, contributes to enhance miR-29 promoter activity. 
On the other hand, miR-214 is also able to promote myogenic differentiation by 
facilitating exit from mitosis via downregulation of neuroblastoma ras oncogene 
(N-ras) [58]. Regarding to the effect that MyoD exerts over miR-214 promoter, 
Naguibneva et al. demonstrated that homeobox A11 (HoxA11), a negative regula-
tor of MyoD expression, is a direct target of miR-181 during mammalian muscle 
differentiation. Thus, under differentiation conditions, miR-181 is upregulated, 
resulting in downregulation of HoxA11 and the consequent release of MyoD expres-
sion [59]. MyoD also binds in close proximity to the miR-378 gene and causes its 
transactivation [60]. Parallelly, this miR targets MyoR mRNA, thus avoiding the 
antagonist effect of MYOR over MYOD, constituting a feed-forward loop where 
MyoD indirectly downregulates MyoR via miR-378 [60]. Besides, by using chicken 
myoblasts, Wang et al. have described how miR-205a is regulated by myogenin 
(MyoG) transcription factor, which can bind to the promoter region of miR-205a 
gene in chicken, thus inducing its expression. The upregulation of miR-205a can 
inhibit myoblast proliferation and promote myoblast differentiation by its repres-
sion on cadherin-11 (CDH11), a crucial regulator of postnatal skeletal growth [61] 
(Table 1 and Figure 2).
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H19 long noncoding RNA and its encoded miRNAs, miR-675-3p, and miR-675-5p 
are expressed in the skeletal muscles and also are upregulated during myoblast dif-
ferentiation and muscle regeneration [62]. Dey et al. have shown that MiR-675-3p 
targets Smad1 and SMAD family member 5 (Smad5) mRNAs, while miR-675-5p 
represses cell division cycle 6 (Cdc6) mRNA. Consequently, through SMAD1 and 
SMAD5 proteins’ downregulation, miR-675-5p induces a repression of BMP pathway 
as well as a repression of DNA replication through CDC6 protein downregulation, thus 
promoting myoblast differentiation [62]. Similarly, Kong et al. have also shown that 
miR-17 targets Ccnd2, Janus kinase 1 (Jak1) and ras homolog family member C (Rhoc) 
mRNAs. These genes are critical for cell proliferation and/or fusion, hence their inhibi-
tion promotes differentiation of precursor muscle cells [63]. In this sense, Wang et al. 
have also shown that miR-34b represses the proliferation and promotes the differentia-
tion of myoblasts by targeting insulin-like growth factor-binding protein 2 (IGFBP2) 
[64] (Table 1 and Figure 2).
miR-664 induces myogenic differentiation through targeting Wnt family 
member 1 (Wnt1), hence blocking the canonical Wnt/β-catenin signaling pathway 
[34]. In this regard, Alexander et al. unraveled a SRF/MRTF-dependent mechanism 
for the induction of miR-199a transcription during myoblast differentiation [65]. 
In this stage, miR-199a represses WNT2, FZD4, and JAG1 and subsequently down-
regulates WNT signaling to allow for normal myogenic differentiation to occur [65]. 
In this work, the authors also indicate that, in previous stages, miR-199a-5p tran-
scription is likewise repressed by YY1, as happened with miR29 promoter (Table 1 
and Figure 2).
miRNAs can also negatively modulate myoblast differentiation. Thus, it has been 
shown that miR-487b must be downregulated in order to avoid its suppressive effect 
over Irs1 mRNA, as happens during proliferation stage [38]. The MEF2 proteins 
are transcription factors that act in conjunction with myogenic regulatory factors 
(MRFs) to regulate muscle differentiation [73]. In this sense, Seok et al. showed that 
miR-155 represses myoblast differentiation by repressing Mef2a mRNA, hence miR-
155 downregulation is necessary to prevent Mef2a downregulation and to induce 
a proper myoblast differentiation [66]. In a newfangled fashion lnc-mg, a long 
noncoding RNA that promotes myoblast differentiation [74] has been described to 
act as a competing endogenous RNA (ceRNA) sponging miR-351, thus reducing the 
effect of miR-351 on its direct target lactamase-β (LACTB) to promote myoblast 
differentiation [67] (Table 1 and Figure 2).
MiRs are also capable to regulate structural proteins needed at last stages of 
myoblast differentiation. Regarding this, Wang et al. showed that miR-23a prevents 
myogenic differentiation through downregulation of fast myosin heavy chain 
isoforms. Thus, downregulation of miR-23a during final steps of muscle differen-
tiation allows myotubes to express the myosin heavy chain genes Myh1, Myh2, and 
Myh4 [68] (Table 1 and Figure 2).
5. miRNAs and muscle cells in muscular dystrophies
Primary muscular disorders are the consequence of a disease that directly affects 
skeletal muscle [75]. Among them, the most important group, in terms of number 
of people affected as well as economic impact generated in the developed world, 
are muscular dystrophies. These pathologies are inherited myogenic disorders 
characterized by progressive muscle wasting and weakness of variable distribution 
and severity [76]. The genes and their protein products that cause most of these 
disorders have now been identified [76]. However, miRNAs misregulation related to 
them still remains poorly understood. In this section, we focus in the understanding 
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of how miRNAs act in regulating muscle cells in the context of Duchenne muscular 
dystrophy (DMD) and myotonic dystrophy (DM), the most common inherited 
muscle diseases of childhood and adulthood, respectively. In addition, we discuss 
current miR-related molecular diagnosis and therapy approaches implemented in 
the field in order to ameliorate the progression of these pathologies by modulating 
muscle precursor biology.
5.1 miRNA in muscle precursor cells in the context of muscular dystrophies
DMD is the most severe form of muscular dystrophies. It is the most common 
inherited muscle disease of childhood afflicting approximately 1 in 3500 young 
males [77]. It is characterized as a muscular disorder caused by mutations in the 
dystrophin gene located on the short arm of the X chromosome. The absence of, or 
defects in, dystrophin results in chronic inflammation, progressive muscle degenera-
tion, and replacement of muscle with fibroadipose tissues [77]. DMD patients often 
lose independent ambulation by the time they reach 13 years of age and generally die 
of respiratory failure in their late teens or early twenties [78]. Myotonic dystrophy 
type 1 (DM1) and type 2 (DM2) represent the most frequent multisystemic muscular 
dystrophies in adulthood [79]. DM1 and DM2 are rare disorders caused by noncod-
ing intragenic repeat tract expansions of CTG (DMPK gene) and CCTG (CNBP1 
gene), which are pathogenic above 50 or 75 units, respectively [80, 81]. DM patients 
have primarily affected skeletal musculature and display muscle weakness (myopa-
thy), muscle wasting (atrophy), and myotonia as the most recognized signs [79, 81]. 
DM1 and DM2 are characterized as multisystem progressive disorders, with the most 
frequent causes of death being respiratory failure and heart conduction defects.
Comprehensive miRNA expression profiling has revealed that miRNA dysregu-
lation is a common feature in DMD and DM muscles. Nevertheless, the specific 
role that this dysregulation exerts over dystrophic muscle precursor cell biology is 
poorly understood. In this sense, Alexander et al. showed that miR-486 is down-
regulated in human DMD myoblast during myogenic differentiation as they are 
compared with wild type [50]. As we have mentioned before, this miR acts as a 
negative regulator of the PTEN/AKT signaling components and their downstream 
effector during skeletal muscle regeneration [50]. Lack of miR-486 PTEN/AKT 
signaling deregulation worsens myoblast differentiation and, consequently, could 
aggravate the DMD phenotype. Hence, modulation of the PTEN/AKT signaling 
pathway through miR-486 expression has the potential to be a therapy for treat-
ing DMD. Nevertheless, this hypothesis remains elusive. The same group has also 
showed that miR-199a is overexpressed in human DMD myoblast during myogenic 
differentiation as they are compared with wild type [65]. As we have mentioned 
before, miR-199a acts as a potential regulator of myogenesis through suppression of 
WNT signaling factors that act to balance myogenic cell proliferation and differen-
tiation. Alexander et al. showed how muscle-specific overexpression of miR-199a 
transcript in vivo results in myofiber disruption and early lethality in zebrafish. 
However, in this work, the authors use a mylz2-promoter sequence to drive miR-
199a-5p expression in skeletal muscle. This promoter is active specifically in zebraf-
ish skeletal muscle fibers, excluding muscle stem cell progenitors [82], hence the 
effect of miR-199a overexpression in muscle precursor cells still remain unknown. 
Nevertheless, modulation of miR-199a also emerges with an important potential 
to be a therapy for treating DMD. In a more specific approach, de Arcangelis et al. 
showed that the expression level of miR-222 was 50% higher in SCs from dystrophic 
mdx muscles than in wild type cells. This leads to the decrease in β1-syntrophin 
expression by specifically binding to the 3′-UTR of β 1-syntrophin, a component 
of dystrophin-associated protein complex (DAPC), suggesting that the absence 
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of β1-syntrophin could worsen the disease [83]. Nevertheless, the authors did not 
explore downstream effects mediated by miR-222 overexpression in SCs, hence its 
impact in muscle precursor cells still remains elusive.
To obtain primary dystrophic muscle precursors cell cultures, either SCs or their 
derived myoblasts, is an extreme difficult task to achieve since their pathological 
backgrounds prevent their proper expansion in vitro. Some groups have tried to par-
tially solve this problem by obtaining myogenic cell lines from dystrophic patients 
derived from immortalized fibroblasts by using retroviral-mediated expression 
of murine MyoD under the control of the Tet-on inducible construct or by trans-
duction of the TERT and inducible Myod genes [84, 85]. By using this approach, 
Fernandez-Costa et al. showed that, as happened in DM1 Drosophila model muscle 
cells, myogenic cell lines derived from DM1 patients showed a downregulation of 
miR-1, miR-7, and miR-10, demonstrating the conservation of miRNA dysregula-
tion triggered by expanded CTG repeats between the Drosophila model and humans 
[85]. Although overexpression of some of their putative targets was validated by 
RT-qPCR, the mechanisms by which this downregulation induces in DM1-myoblast 
maturation still remains unknown. Similarly, Cappella et al. showed a significant 
miRNA29c downregulation in human DM1 myotubes [84]. Since miRNA29c targets 
ankyrin repeat and SOCS box containing 2 (Asb2), a subunit of a multimeric E3 
ubiquitin-ligase complex that negatively regulates muscle fiber mass [84], miR-
NA29c downregulation in DM1 could affect total muscle mass and worsen disease 
progression. In agreement with Cappella et al., Wang et al. (2012) have demon-
strated that the loss of miR-29 impairs myogenic differentiation in mdx myoblasts 
[86]. This impairment may be due to the control exercised by miR29 in fibrosis.
In this regard, we must stress that miR-29-family miRNAs display a crucial role 
in the regulation of extracellular matrix genes and in fibrosis [87]. The replacement 
of muscle with fibroadipose tissues is a major pathological hallmark of DMD and 
DM [77, 84]. The canonical TGF-β/Smad signaling pathway, a well-known pathway 
involved in fibrosis formation, appears to negatively regulate the expression of miR-
29, thereby promoting the conversion of myoblasts in myofibroblasts [86, 88]. During 
this transdifferentiation, activated TGF-β signaling induces Smad3 translocation 
into nucleus where it binds to miR-29 promoter, resulting in MyoD dissociation as 
well as YY1/Ezh2 stabilization. This causes a loss of miR-29 expression and increased 
expression of collagens and Lims1, leading to the transdifferentiation of myoblasts 
into myofibroblasts. All together, these data suggest that miR-29 could be an impor-
tant molecular target for treating fibrosis associated to DMD and DM phenotypes.
Beyond the mere description, the works presented in this section provide us 
with very valuable information that can help us find new therapeutic targets on 
which to focus the development of drugs that would help us to alleviate the effects 
of dystrophic pathologies. We will discuss this issue in the next section.
5.2 miRNA as therapeutic targets in DMD and DM
As we have previously illustrated, several miRNAs are significantly dysregulated 
in DMD and DM muscular dystrophies and are able to modify muscle cell behavior 
in this context. For those downregulated, miRNA replacement can be conducted 
to restore its function by introducing a miRNA mimic product. The miR mimic 
technology utilizes synthetic, modified oligonucleotides that can bind to the unique 
sequence of target genes (mRNAs) in a gene-specific manner and elicit posttran-
scriptional repressive effects as an endogenous miRNA does [89]. Alternatively, 
application of miR mimics targeting the disease-causing genes to prevent their 
upregulation may be an efficient maneuver to tackle the problem [89]. For those 
miRNAs upregulated, inhibition can be conducted by using antimiR products. 
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Different types of antimiR products exist based on their mechanism of action. As 
happens for the miRNA mimic product, antimiRs comprise numerous classes of 
chemically modified oligonucleotides and nucleic acid analogs like locked nucleic 
acids (LNAs), 2′-O-methyl (2′-O-Me) oligos, 2′-O-methoxyethyl (2′-O-MOE) 
oligos, antagomiRs, peptide nucleic acids (PNAs), and phosphorodiamidate mor-
pholinos (PMOs) [90]. These chemical modifications are implemented to provide 
resistance to cellular nucleases and to increase affinity toward complementary 
miRNA sequences [91, 92]. In addition, some antimiRs have flanking sequences or 
are connected to lipids through the use of linkers [93]. All the molecules that we 
have mentioned so far induce transient effects either because they are diluted by 
successive cell divisions or because they are metabolized in the cytoplasm [93]. To 
achieve long-term suppression of a specific miRNA, specialized plasmid and virus 
vectors carrying expression units for these inhibitory RNA molecules have also been 
developed [94]. In this regard, as an alternative to chemically modified antisense 
oligonucleotides, Ebert et al. developed miRNA inhibitors that can be expressed 
in cells as RNAs produced from transgenes [95]. Termed “miRNA sponges,” these 
competitive inhibitors are transcripts expressed from strong promoters, containing 
multiple, tandem binding sites to an miRNA of interest. When vectors encod-
ing these sponges are transfected into cultured cells, sponges derepress miRNA 
targets at least as strongly as chemically modified antisense oligonucleotides [95]. 
Muscular dystrophy Molecular approach Mimic/target 
miRNA
References
Duchenne muscular 
dystrophy
miRNA mimic/antimiR miR-21 [97, 98]
miRNA mimic miR-29 [86, 97, 99]
miRNA sponge miR-31 [100]
miRNA mimic/antimiR miR-34c [101]
miRNA mimic/antimiR miR-188 [102]
miRNA sponge miR-206 [103]
miRNA mimic miR-431 [104]
miRNA mimic/antimiR miR-675 [98]
miRNA mimic/antimiR miR-708 [101]
miRNA mimic miR-10 [85]
miRNA sponge miR-277 [105]
Myotonic dystrophy miRNA sponge miR-304 [105]
antimiR miR-23b [106]
antimiR miR-218 [106]
miRNA mimic miR-1 [107, 108]
miRNA mimic miR-206 [107, 109]
miRNA mimic miR-148a [107]
miRNA mimic miR-214 [107]
miRNA mimic miR-15b [107]
miRNA mimic miR-16 [107]
miRNA mimic miR-30 [110]
Table 2. 
miRs’ therapeutic assays in animal models.
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These miRNA sponge vectors inhibit miRNA function efficiently but for no longer 
than 1 month [96]. This problem has been partially solved by the development of 
“tough decoy RNAs” technology [93, 96]. Tough decoy inhibitor is a 60 base pair 
long hairpin-shaped inhibitor with a large internal bulge containing two miRNA 
recognition sites [93, 96]. Through plasmid- or lentivirus-based vectors, these 
molecules are efficiently exportable to the cytoplasm, where they target the highly 
potent miRNA inhibitory system which persists for well over 1 month [93, 96]. 
In the field of muscular dystrophies, many of these approaches have been tested 
in vitro and in vivo with animal models (Table 2). However, doubts related to 
the safety and efficiency of delivery still discourage the use of these molecules in 
humans.
6. Conclusions and perspectives
At present, a critical point for the development of effective strategies for treating 
muscle disorders is optimizing approaches to target muscle stem cells in order to increase 
the ability to regenerate lost tissue. In the context of muscle regeneration, emerging 
scientific evidence supports that miRNAs play a critical role in skeletal muscle, as they 
are required for the development and differentiation of this tissue. In addition, deregula-
tion of miRNAs in muscle degenerative diseases suggests that gene-based therapies of 
miRNAs can be effective in treating muscle-related disorders. In this sense, restoration 
of non-pathological level of miRs expression would help to ameliorate these pathologies. 
Although many in vitro approaches have been accomplished in this regard, in vivo strate-
gies remain poorly explored since the main shortcoming of the field lies in the ineffec-
tive delivery of either mimics or antimiR molecules. These molecules must overcome 
numerous roadblocks as canonical physiological pharmacokinetic and cellular uptake 
barriers as well as noncanonical barriers, such as intracellular miRNA localization and 
trafficking, off-target toxicities, and other intrinsic limitations. Improvement in this task 
will be the upcoming challenge for the next years by looking for strategies that allow us 
to aim these molecules in a specific fashion to muscle progenitor cells, thus minimizing 
the off-target effects of non-muscle tissues.
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